UNRESECTABLE UROTHELIAL CARCINOMA
Clinical trials for UNRESECTABLE UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to shrink tough bladder tumors
Disease control Recruiting nowThis early-phase trial tests a combination of two drugs, cabozantinib and enfortumab vedotin, in people with advanced bladder cancer that has spread or cannot be removed. The goal is to find the best dose and see if the combo is safe and shrinks tumors. About 32 adults who have a…
Matched conditions: UNRESECTABLE UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
Tailor-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…
Matched conditions: UNRESECTABLE UROTHELIAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New combo aims to outsmart resistant bladder cancer in phase 3 trial
Disease control Recruiting nowThis phase 3 trial tests whether combining two drugs—pembrolizumab (an immunotherapy) and sacituzumab govitecan (a targeted chemo)—works better than standard chemotherapy for people with advanced bladder cancer that no longer responds to initial immunotherapy. About 320 adults wi…
Matched conditions: UNRESECTABLE UROTHELIAL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New combo therapy aims to keep advanced bladder cancer at bay
Disease control Recruiting nowThis study tests a two-step treatment for people with advanced bladder cancer that has spread. First, patients receive a combination of two drugs (enfortumab vedotin and pembrolizumab) for 18 weeks. Then, those who respond well continue with just pembrolizumab for up to 2 years t…
Matched conditions: UNRESECTABLE UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:02 UTC
-
New combo aims to outsmart Drug-Resistant bladder cancer
Disease control Recruiting nowThis early-stage trial tests a new drug combination (emavusertib plus pembrolizumab) in 27 adults with advanced bladder cancer that no longer responds to standard immunotherapy. The goal is to find a safe dose and see if the combo can shrink tumors or slow the cancer's growth. Pa…
Matched conditions: UNRESECTABLE UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 05, 2026 11:56 UTC
-
Cancer patients may soon get immunotherapy at home – no more long clinic trips!
Symptom relief Recruiting nowThis study looks at whether giving the cancer drug nivolumab as a shot at home is as good as getting it at the clinic. About 50 adults with various cancers will try both ways to see which they prefer and how it affects their quality of life. The goal is to reduce the time, cost, …
Matched conditions: UNRESECTABLE UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated May 17, 2026 02:17 UTC